Cancer-associated Fibroblasts Actively Compress Cancer Cells and Modulate Mechanotransduction
Overview
Authors
Affiliations
During tumor progression, cancer-associated fibroblasts (CAFs) accumulate in tumors and produce an excessive extracellular matrix (ECM), forming a capsule that enwraps cancer cells. This capsule acts as a barrier that restricts tumor growth leading to the buildup of intratumoral pressure. Combining genetic and physical manipulations in vivo with microfabrication and force measurements in vitro, we found that the CAFs capsule is not a passive barrier but instead actively compresses cancer cells using actomyosin contractility. Abrogation of CAFs contractility in vivo leads to the dissipation of compressive forces and impairment of capsule formation. By mapping CAF force patterns in 3D, we show that compression is a CAF-intrinsic property independent of cancer cell growth. Supracellular coordination of CAFs is achieved through fibronectin cables that serve as scaffolds allowing force transmission. Cancer cells mechanosense CAF compression, resulting in an altered localization of the transcriptional regulator YAP and a decrease in proliferation. Our study unveils that the contractile capsule actively compresses cancer cells, modulates their mechanical signaling, and reorganizes tumor morphology.
tailored confining microenvironment for lung cancer spheroids.
Dong Y, Qian S, Wang X, Zhang W, Lu W, Qu J Mater Today Bio. 2025; 31:101602.
PMID: 40070872 PMC: 11894329. DOI: 10.1016/j.mtbio.2025.101602.
The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.
Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.
PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.
Xie M, Qin H, Liu L, Wu J, Zhao Z, Zhao Y J Exp Clin Cancer Res. 2025; 44(1):61.
PMID: 39972344 PMC: 11837350. DOI: 10.1186/s13046-025-03315-9.
Maiques O, Sallan M, Laddach R, Pandya P, Varela A, Crosas-Molist E Nat Commun. 2025; 16(1):1394.
PMID: 39952917 PMC: 11829002. DOI: 10.1038/s41467-025-56299-7.
Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing.
Perucca A, Llonin A, Benach O, Hallopeau C, Rivas E, Linares J Nat Commun. 2025; 16(1):1279.
PMID: 39900918 PMC: 11790944. DOI: 10.1038/s41467-025-56275-1.